Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

Biocon strategically uses its stable, cash-generating generics business to finance the capital-intensive development and scaling of its high-growth biosimilar platform. This creates a self-sustaining financial model where the mature business fuels the emerging one, enabling reinvestment into R&D and manufacturing without heavy reliance on external capital.

Rather than lobbying regulatory bodies and policymakers as a single entity, Biocon gains influence by actively participating in industry-wide associations like the Biosimilar Forum and Medicines for Europe. This collective approach creates a unified voice for the industry, allowing manufacturers to effectively shape policy and promote a "biosimilar first" strategy.

In markets like biosimilars, price erosion is a constant reality. Success requires a continuous pipeline of new product launches each year. These launches provide the necessary revenue "lift" to counteract the natural deflation of existing products in the portfolio, ensuring sustained growth and market leadership.

When choosing between a bundled, vertically integrated solution and an unbundled "wedge" approach, the answer is not universal. According to Eric Byunn, it requires deep understanding of the specific industry's complex value chain, including the incentives and economics for each party involved. Both strategies can work.

When a pharmaceutical company gets a new drug approved, the specific containment system (e.g., Stevanato's vial) is part of the FDA filing. To switch suppliers, the pharma company must repeat a multi-year, multi-million dollar approval process. This "spec-in" dynamic creates immense customer lock-in and long-term revenue visibility.

Regeneron maintains a competitive edge by owning its antibody discovery platform (mice with humanized immune systems). This vertical integration provides full control and consistently yields best-in-class molecules, a feat competitors struggle to replicate even with access to similar third-party services.

With costs of $50-$150 million to bring a single biosimilar to market, the industry has significant barriers to entry. This financial reality will drive consolidation over the next 3-5 years, as smaller, single-product companies (or "one-hit wonders") will struggle to compete with scaled, well-capitalized players like Biocon that possess a robust and diverse product pipeline.